- Home
- KOD vs IVA Comparison
KOD vs IVA Comparison
Compare KOD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- IVA
- Stock Information
- Founded
- KOD 2009
- IVA 2011
- Country
- KOD United States
- IVA France
- Employees
- KOD N/A
- IVA N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- IVA Health Care
- Exchange
- KOD Nasdaq
- IVA Nasdaq
- Market Cap
- KOD 186.3M
- IVA 117.3M
- IPO Year
- KOD 2018
- IVA 2020
- Fundamental
- Price
- KOD $8.72
- IVA $2.35
- Analyst Decision
- KOD Hold
- IVA Strong Buy
- Analyst Count
- KOD 5
- IVA 4
- Target Price
- KOD $6.80
- IVA $13.25
- AVG Volume (30 Days)
- KOD 473.7K
- IVA 9.3K
- Earning Date
- KOD 11-14-2024
- IVA 09-25-2024
- Dividend Yield
- KOD N/A
- IVA N/A
- EPS Growth
- KOD N/A
- IVA N/A
- EPS
- KOD N/A
- IVA N/A
- Revenue
- KOD N/A
- IVA $20,652,523.00
- Revenue This Year
- KOD N/A
- IVA N/A
- Revenue Next Year
- KOD N/A
- IVA $361.78
- P/E Ratio
- KOD N/A
- IVA N/A
- Revenue Growth
- KOD N/A
- IVA N/A
- 52 Week Low
- KOD $2.19
- IVA $1.53
- 52 Week High
- KOD $11.60
- IVA $4.75
- Technical
- Relative Strength Index (RSI)
- KOD 64.72
- IVA 36.64
- Support Level
- KOD $8.03
- IVA $2.22
- Resistance Level
- KOD $9.55
- IVA $2.39
- Average True Range (ATR)
- KOD 0.89
- IVA 0.10
- MACD
- KOD -0.08
- IVA -0.03
- Stochastic Oscillator
- KOD 36.51
- IVA 24.76
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.